Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Nov. 14, 2013, 154 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $292.50 to $467,462,888.00. Highlighted Stocks Traded by Insiders: Inovio Pharmaceuticals (INO) - FREE Research Report Collins Morton who is Director at Inovio Pharmaceuticals bought 254,500 shares at $1.82 on Nov. 14, 2013. Following this transaction, the Director owned 730,864 shares meaning that the stake was reduced by 53.43% with the 254,500 share transaction. The shares most recently traded at $2.03, up $0.21, or 10.32% since the insider transaction. The average volume for Inovio Pharmaceuticals has been 6.6 million shares per day over the past 30 days. Inovio Pharmaceuticals has a market cap of $389.7 million and is part of the health care sector and drugs industry. Shares are up 274.37% year to date as of the close of trading on Thursday. Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 5 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on INO - FREETheStreet Quant Ratings rates Inovio Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Inovio Pharmaceuticals Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.